# Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

> **NCT03788291** · PHASE2 · COMPLETED · sponsor: **University of Rochester** · enrollment: 39 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03788291
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2023-05-19
- **Final completion:** 2023-05-19
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03788291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03788291, "Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03788291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*